Tesamorelin is a peptide primarily used toreduce excess visceral abdominal fat, especially in adults with HIV-related lipodystrophy. Visceral fat is a type of fat that surrounds internal organs and is linked to health problems like cardiovascular disease and metabolic dysfunction.
By mimicking a natural hormone, tesamorelin stimulates the pituitary gland to produce and release more growth hormone (GH), which, in turn, boosts levels of insulin-like growth factor-1 (IGF-1). This process drives the key benefits associated with the drug.
Clinically recognized benefits
Reduces visceral fat:Tesamorelin is most known for its ability to target and reduce visceral adipose tissue (VAT). Clinical studies in HIV patients with lipodystrophy showed that tesamorelin can reduce VAT by as much as 18–20%.
Improves liver health:Research has shown that tesamorelin can decrease fat accumulation in the liver, which is particularly beneficial for individuals with non-alcoholic fatty liver disease (NAFLD), a condition often linked to metabolic disorders.
Enhances body composition:By reducing visceral fat while helping to preserve or increase lean muscle mass, tesamorelin can improve overall body composition.
Improves cardiovascular risk factors:The reduction in visceral fat can lead to enhanced lipid profiles, including lower triglyceride levels, which improves cardiovascular health.
Supports cognitive function:Studies have indicated that higher levels of GH and IGF-1 stimulated by tesamorelin may contribute to improved cognitive function, memory, and mood.
You may also like
Join the Revolution
Subscribe for insights and innovations that redefine laboratory excellence.